| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/06/2013 | CA2556305C Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity |
| 08/06/2013 | CA2552228C Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
| 08/06/2013 | CA2540308C Drug coating providing high drug loading and methods for providing the same |
| 08/06/2013 | CA2540059C Controlled release formulations exhibiting an ascending rate of release |
| 08/06/2013 | CA2532865C Fluoro substituted omega-carboxyaryl diphenyl urea for the inhibition of kinase signaling |
| 08/06/2013 | CA2532473C Amino acid supplementation for a healthy microbiota ecosystem |
| 08/06/2013 | CA2531859C Benzimidazole derivatives as raf kinase inhibitors |
| 08/06/2013 | CA2529949C Antiviral compounds and methods |
| 08/06/2013 | CA2522580C A medicament for the two-step perioperative therapy of solid tumours |
| 08/06/2013 | CA2520957C Method for treating vascular hyperpermeable disease |
| 08/06/2013 | CA2519429C Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics |
| 08/06/2013 | CA2458016C Paper product with disinfecting properties |
| 08/06/2013 | CA2451839C Pharmaceutical compositions comprising peptides and permeation enhancers |
| 08/06/2013 | CA2442118C Improved edible compositions for lowering cholesterol |
| 08/06/2013 | CA2425779C Compositions that inhibit proliferation of cancer cells |
| 08/06/2013 | CA2388807C Viruses for the treatment of cellular proliferative disorders |
| 08/03/2013 | CA2805471A1 Slow release pharmaceutical compound of trimetazidine |
| 08/01/2013 | WO2013113030A2 Fads regulation |
| 08/01/2013 | WO2013113000A2 Detection of dna sequences as risk factors for hiv infection |
| 08/01/2013 | WO2013112959A1 Antifibrotic compounds and uses thereof |
| 08/01/2013 | WO2013112951A2 Treatment of circadian rhythm disorders |
| 08/01/2013 | WO2013112950A2 Certain chemical entities, compositions, and methods |
| 08/01/2013 | WO2013112949A2 Treatment of circadian rhythm disorders |
| 08/01/2013 | WO2013112942A1 Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| 08/01/2013 | WO2013112932A1 Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| 08/01/2013 | WO2013112897A1 Stabilization of biomolecules using sugar polymers |
| 08/01/2013 | WO2013112881A1 Mct protein inhibitor-related prognostic and therapeutic methods |
| 08/01/2013 | WO2013112878A1 Mcl-1 modulating compositions |
| 08/01/2013 | WO2013112876A1 Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof |
| 08/01/2013 | WO2013112873A2 Compositions and methods for improving lactation |
| 08/01/2013 | WO2013112850A1 Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof |
| 08/01/2013 | WO2013112809A2 Rifaximin derivative and uses thereof |
| 08/01/2013 | WO2013112804A1 Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| 08/01/2013 | WO2013112788A1 Compounds for treating spinal muscular atrophy |
| 08/01/2013 | WO2013112762A1 Bendamustine compositions and methods therefore |
| 08/01/2013 | WO2013112757A1 Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| 08/01/2013 | WO2013112751A1 Potent non-urea inhibitors of soluble epoxide hydrolase |
| 08/01/2013 | WO2013112741A1 Apoptosis signal-regulating kinase inhibitor |
| 08/01/2013 | WO2013112734A1 Sustained drug delivery from solid implants with nanochannel membranes |
| 08/01/2013 | WO2013112722A1 Inhibitors of rho associated protein kinases (rock) and methods of use |
| 08/01/2013 | WO2013112706A1 Proteasome activity modulating compounds |
| 08/01/2013 | WO2013112699A2 Proteasome activity enhancing compounds |
| 08/01/2013 | WO2013112673A1 Synthetic voacangine |
| 08/01/2013 | WO2013112651A2 Proteasome activity modulating compounds |
| 08/01/2013 | WO2013112622A1 (1r,4r) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof |
| 08/01/2013 | WO2013112605A2 Neuroactive steroid formulations and methods of treating cns disorders |
| 08/01/2013 | WO2013112456A1 Controlled release formulations for the induction and proliferation of blood cells |
| 08/01/2013 | WO2013112416A1 Clear solid sticks with solubilized pharmaceutical agents |
| 08/01/2013 | WO2013112363A1 Method of treating tourette's disorder with gaba-aminotransferase inactivators |
| 08/01/2013 | WO2013112323A1 Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors |
| 08/01/2013 | WO2013112072A1 Complexes of germanium with amino acids and carboxylic acids and method for preparing same |
| 08/01/2013 | WO2013111969A1 Composition containing tanshinone as active ingredient, for increasing differentiation or activity of natural killer cells |
| 08/01/2013 | WO2013111946A1 Method for preparing rosuvastatin, and intermediate compound used in preparing rosuvastatin |
| 08/01/2013 | WO2013111924A1 Novel compound derived from ishige foliacea, and use thereof |
| 08/01/2013 | WO2013111897A1 Novel antitumor agent and method for screening same |
| 08/01/2013 | WO2013111870A1 Therapeutic agent for diabetes |
| 08/01/2013 | WO2013111850A1 Chromone derivative having osteogenesis promoting effect |
| 08/01/2013 | WO2013111831A1 Pyrrole compound |
| 08/01/2013 | WO2013111823A1 Method for producing sphingoid base-containing extract |
| 08/01/2013 | WO2013111817A1 Oil-in-water-type creamy composition containing tacrolimus |
| 08/01/2013 | WO2013111801A1 Triblock copolymer and use thereof |
| 08/01/2013 | WO2013111799A1 Brain function improver |
| 08/01/2013 | WO2013111798A1 Serine racemase inhibitor |
| 08/01/2013 | WO2013111796A1 N-substituted pyrazole derivative |
| 08/01/2013 | WO2013111729A1 Pharmaceutical composition and quasi-drug cosmetic using same |
| 08/01/2013 | WO2013111714A1 Prophylactic or therapeutic agent for bronchial asthma and method for screening same |
| 08/01/2013 | WO2013111393A1 Hair growing agent |
| 08/01/2013 | WO2013111157A1 Process for preparing amorphous cabazitaxel |
| 08/01/2013 | WO2013111150A1 Derivatives of aza adamantane and uses thereof |
| 08/01/2013 | WO2013111132A1 Treatment of liver conditions |
| 08/01/2013 | WO2013111118A2 Agents for treating neurodegenerative disorders |
| 08/01/2013 | WO2013111117A2 Agents for treating mental disorders |
| 08/01/2013 | WO2013111107A1 Aminopyridine derivatives as plasma kallikrein inhibitors |
| 08/01/2013 | WO2013111106A1 Pyrimidooxazocine derivatives as mtor - inhibitors |
| 08/01/2013 | WO2013111105A1 Imidazopyrrolidinone compounds |
| 08/01/2013 | WO2013111085A1 Pharmaceutical composition for the treatment of erectile dysfunction |
| 08/01/2013 | WO2013111081A1 Treatment of disease by modulation of sirt6 |
| 08/01/2013 | WO2013111077A1 Pharmaceutical composition as a substance for antireflux antacid drug |
| 08/01/2013 | WO2013111066A2 New pharmaceutical compositions containing phosphatidylserine and curcumin |
| 08/01/2013 | WO2013110975A1 Improved nitazoxanide composition and preparation method thereof |
| 08/01/2013 | WO2013110890A1 New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same |
| 08/01/2013 | WO2013110830A1 Pharmaceutical composition comprising isometamidium chloride in solution for the treatment of trypanosomiasis in animals |
| 08/01/2013 | WO2013110796A1 Thiazolidinedione derivatives, preparation thereof and use thereof in cancer treatment |
| 08/01/2013 | WO2013110768A1 Pde9 inhibitors with imidazo triazinone backbone |
| 08/01/2013 | WO2013110756A1 Ingenol mebutate in combination with cryotherapy for the treatment of actinic keratosis |
| 08/01/2013 | WO2013110704A1 Novel galactoside inhibitors of galectins |
| 08/01/2013 | WO2013110698A1 Substituted pyrano and furanoquinolines, their preparation and use as medicaments |
| 08/01/2013 | WO2013110644A1 Pharmaceutical composition containing crystalline sorafenib tosylate |
| 08/01/2013 | WO2013110643A1 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents |
| 08/01/2013 | WO2013110632A1 Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation |
| 08/01/2013 | WO2013110622A1 Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
| 08/01/2013 | WO2013110590A1 Substituted phenylimidazopyrazoles and use thereof |
| 08/01/2013 | WO2013110585A1 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors |
| 08/01/2013 | WO2013110567A1 Novel orally administered dabigatran formulation |
| 08/01/2013 | WO2013110442A1 Thin film drug delivery system for the transmucosal administration of a 1,4- benzoquinone derivative |
| 08/01/2013 | WO2013110433A1 Azaheterocyclic compounds |
| 08/01/2013 | WO2013110358A1 Hedgehog signaling pathway involved in energy metabolism |
| 08/01/2013 | WO2013110354A1 Compositions and methods for cell transplantation |
| 08/01/2013 | WO2013110309A1 Triazolo[4,5-d]pyrimidine derivatives |
| 08/01/2013 | WO2013110280A1 Panobinostat for use in the treatment of hiv-1 |